The setup, per Lilly's investor disclosures and ClinicalTrials.gov: Duration: 80 weeks of treatment (the longest of any TRIUMPH trial) Population: Adults with obesity (BMI 30) or overweight (BMI 27) plus at least one weight-related comorbidity, without type 2 diabetes Doses: 4 mg, 8 mg, and 12 mg retatrutide vs matched placebo, all once-weekly subcutaneous Primary endpoints: Mean percent change in body weight
Do not use this calculator to change your prescribed plan
A licensing decision, if it comes, would still need to happen before legal routine supply
These trials have shown reductions in heart failure symptoms and physical limitations and greater improvement in exercise function and have led to growing interest in new ways to address HFpEF, a condition with limited guideline direct medication therapy compared to heart failure with reduced ejection fraction (HFrEF)
Calling $69 membership a GLP-1 plan when it doesnt include GLP-1 medication is false advertising, plain and simple
GLP-1 patches are advertised as an easy, non-invasive way to support weight loss